Genmab A GMAB
NASDAQ GMAB
$54.07 -1.74 (-3.12%)
At close: Nov 10, 2026 · 4:00 PM EST

Genmab A (GMAB) Amortization - Intangibles (2025 - 2026)

Updated

Analysis

Genmab A (GMAB) Amortization - Intangibles (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Genmab A 3.47 Bn -3.13 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -11.00 Mn
Sep 30, 2025 -3.00 Mn
API Access

Genmab A Amortization - Intangibles API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-intangibles&ticker=GMAB&period=max&api_key=YOUR_API_KEY